Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
Safety Advices
বাংলা
English
CAUTION
Caution is advised when consuming alcohol with Dexinaaf 30. Please consult your doctor.
SAFE IF PRESCRIBED
Dexinaaf 30 is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
SAFE IF PRESCRIBED
Dexinaaf 30 is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
CONSULT YOUR DOCTOR
It is not known whether Dexinaaf 30 alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
SAFE IF PRESCRIBED
Dexinaaf 30 is safe to use in patients with kidney disease. No dose adjustment of Dexinaaf 30 is recommended.
CAUTION
Dexinaaf 30 should be used with caution in patients with liver disease. Dose adjustment of Dexinaaf 30 may be needed. Please consult your doctor.
Medicine Overview of Dexinaaf 30mg capsule
Introduction
Dexinaaf 30 is a medicine that reduces the amount of acid produced in your stomach. It is used for treating acid-related diseases of the stomach and intestine such as heartburn, acid reflux, peptic ulcer disease, and some other stomach conditions associated with excessive acid production. Dexinaaf 30 is also used to prevent stomach ulcers and acidity that may be seen with the prolonged use of pain-killers. It belongs to a class of medicines known as proton pump inhibitors (PPIs). This medicine should be taken one hour before a meal, preferably in the morning. The dose will depend on your underlying...
... Show moreUses of Dexinaaf 30
- Gastroesophageal reflux disease (Acid reflux)
- Peptic ulcer disease
Side effects of Dexinaaf 30
Common
- Nausea
- Abdominal pain
- Flatulence
- Diarrhea
- Vomiting
How to use Dexinaaf 30
Take this medicine in the dose and duration as advised by your doctor. Do not chew, crush or break it. Dexinaaf 30 is to be taken empty stomach.
How Dexinaaf 30 works
Dexinaaf 30 is a proton pump inhibitor (PPI). It works by reducing the amount of acid in the stomach which helps in relief of acid related indigestion and heartburn.
What if you forget to take Dexinaaf 30?
If you miss a dose of Dexinaaf 30, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
Quick Tips
- Dexinaaf 30 should be taken 1 hour before a meal, preferably in the morning.
- It is a well-tolerated medicine and provides relief for a long time.
- Avoid eating late at night or before bedtime.
- Inform your doctor if you get watery diarrhea, fever or stomach pain that does not go away.
- Inform your doctor if you do not feel better after taking it for 14 days as you may be suffering from some other problem that needs attention.
- Long-term use of Dexinaaf 30 can cause weak bones and a deficiency of minerals such as magnesium. Take adequate dietary intake of calcium and magnesium or their supplements as prescribed by your doctor.
- Consult your doctor right away if you develop decreased urination, edema (swelling due to fluid retention), lower back pain, nausea, fatigue, and rash or fever. These could be signs of a kidney problem.
Brief Description
Indication
Oesophagitis, Gastro-oesophageal reflux disease (GERD)
Administration
Capsule: May take with or without food
DR: Take at least 30 minutes before a meal
Adult Dose
Erosive Esophagitis
Capsule: Indicated for healing of all grades of erosive esophagitis (EE) and maintaining healing of EE
DR: Indicated for maintaining healing of EE
Healing (capsule): 60 mg PO qDay for up to 8 weeks
Maintenance (capsule or DR): 30 mg PO qDay for up to 6 months
Gastroesophageal Reflux Disease
Indicated for treating heartburn associated with symptomatic nonerosive GERD
Capsule or DR: 30 mg PO qDay for 4 weeks
Hepatic impairment
Milde (Child-Pugh A): Dose adjustment not necessary
Moderate (Child-Pugh B): Not to exceed 30 mg/day
Severe (Child-Pugh C): Not recommended
Child Dose
12 years
Erosive Esophagitis
Capsule: Indicated for healing of all grades of erosive esophagitis (EE) and maintaining healing of EE
DR: Indicated for maintaining healing of EE
Healing (capsule): 60 mg PO qDay for up to 8 weeks
Maintenance (capsule or DR): 30 mg PO qDay for up to 6 months
Gastroesophageal Reflux Disease
Indicated for treating heartburn associated with symptomatic nonerosive GERD
Capsule or DR: 30 mg PO qDay for 4 weeks
Contraindication
Hypersensitivity.
Mode of Action
R-enantiomer of lansoprazole; PPI; binds to H+/K+-exchanging ATPase (proton pump) in gastric parietal cells, resulting in blockage of acid secretion.Dual release formulation.
Precaution
Hepatic impairment. Gastric malignancy should be ruled out. Pregnancy and lactation.
Lactation
Risk Summary
There is no information regarding presence of dexlansoprazole in human milk, effects on breastfed infant, or on milk production; however, lansoprazole and its metabolites are present in rat milk; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and potential adverse effects on breastfed child from therapy or from the underlying maternal condition
Side Effect
1-10%
Diarrhea (5%),Abdominal pain (4%),Nausea (3%),URI (2-3%),Vomiting (1-2%),Flatulence (1%)
<1% (Selected)
Arrhythmia,Bradycardia,Barrett's esophagus,DVT,Dyspnea,Hepatomegaly,Hypertension,Paresthesia,Rectal hemorrhage,Vulvovaginal infection
Pregnancy Category Note
Pregnancy There are no studies with dexlansoprazole use in pregnant women to inform a drug-associated risk; dexlansoprazole is R-enantiomer of lansoprazole, and published observational studies of lansoprazole use during pregnancy did not demonstrate an association of adverse pregnancy-related outcomes with lansoprazole In animal reproduction studies, oral administration of lansoprazole to rats during organogenesis through lactation at 1.8 times the maximum recommended human dexlansoprazole dose; produced reductions in the offspring in femur weight, femur length, crown-rump length and growth plate thickness (males only) on postnatal day 21; these effects were associated with reduction in body weight gain; advise pregnant women of...
... Show moreInteraction
Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate.
Potentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
